Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults

Papp, Kim; Papp, Alexine; Dahmer, Betty; Clark, Christina

doi:10.1016/j.jaad.2011.02.032

Cited by 30 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are similar to those from previous studies that evaluated the efficacy of topical sertaconazole in patients with SD (Elewski and Cantrell, 2011, Firooz et al, 2006, Goldust et al, 2013a, Goldust et al, 2013b, Papp et al, 2012). In a double-blind, randomized, controlled study, Goldust et al (2013a) compared the efficacy of twice daily application of topical hydrocortisone 1% with that of topical sertaconazole in 69 consecutive patients in each treatment group.…”

Section: Discussionsupporting

confidence: 91%

“…Corticosteroid treatments are generally used to reduce inflammation. Hydrocortisone is a mild topical corticosteroid that is used to reduce swelling, redness, and itching in various inflammatory skin disorders including SD (Papp et al, 2012, Rovelli et al, 2011). A new imidazole antifungal agent that is used in the treatment of SD is sertaconazole, which inhibits the synthesis of ergosterol in the cell wall of fungi (Weinberg and Koestenblatt, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial

Balighi

Ghodsi

Daneshpazhooh

et al. 2017

International Journal of Women's Dermatology

View full text Add to dashboard Cite

BackgroundSeborrheic dermatitis (SD) is a chronic dermatitis with periods of remission and relapse that requires long-term treatment.ObjectiveWe compared the efficacy and safety of treatment with sertaconazole with standard corticosteroid medications in adults with facial SD.MethodsIn this double-blind, randomized controlled trial, 60 patients with a diagnosis of SD were enrolled. Patients were instructed to apply either sertaconazole 2% cream (30 patients) or hydrocortisone 1% cream (30 patients) twice daily to the affected area of the face. The severity of facial SD was assessed at 0, 2, and 4 weeks of treatment. Secondary efficacy measures included patient assessment of seborrhea, adverse events, and improvement percentage (IP).ResultsSD lesions cleared significantly (p < .05) and similarly in both treatment groups (p > .05). Both treatments resulted in significant improvement of SD lesions and the rate of adverse events was similar in both groups. The IP was higher for treatment with hydrocortisone in Week 2 and similar in both groups at the end of the study.LimitationsLimitations include the small number of patients who were recruited for this study and the lack of evaluation of time to relapse.ConclusionTreatment with topical sertaconazole may be regarded as a substitute for topical corticosteroid medications due to the fewer adverse events and similar efficacy.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial

Balighi

Ghodsi

Daneshpazhooh

et al. 2017

International Journal of Women's Dermatology

View full text Add to dashboard Cite

show abstract

“…It is characterized by scaly, erythematous lesions typically in sebum-rich areas of the skin such as scalp, face, trunk, and intertriginous areas [2,3]. The etiology of SD is not fully known but several Trial registration: IRCT2012091510842N1 (www.irct.ir).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial

2015

View full text Add to dashboard Cite

show abstract

“…Tacrolimus application resulted in complete clearance in 61% of the patients, while the remaining patients showed a marked improvement at the end of the treatment. Another study compared the efficacy and safety of tacrolimus with those of standard corticosteroid treatments for adult facial SD and showed that significantly fewer applications of 0.1% tacrolimus ointment were required compared with 1% hydrocortisone ointment to achieve a comparable clinical response in adult facial SD (13). Although prevention strategies of relapse of SD have not yet been established, there have been some reports on the use of anti-Pityrosporum (anti-dandruff) shampoo prophylaxis for SD of the scalp (14)(15)(16).…”

Section: Discussionmentioning

confidence: 99%

Proactive Treatment of Adult Facial Seborrhoeic Dermatitis with 0.1% Tacrolimus Ointment: Randomized, Double-blind, Vehicle-controlled, Multi-centre Trial

Kim¹,

Mun²,

Jwa³

et al. 2013

Acta Derm Venerol

View full text Add to dashboard Cite

The effectiveness of intermittent topical tacrolimus to prevent relapse in patients with stabilized facial seborrhoeic dermatitis has not been evaluated. The aim of this study was to determine whether proactive use of 0.1% tacrolimus ointment can keep adult facial seborrhoeic dermatitis in remission. A total of 75 patients who had stabilized facial seborrhoeic dermatitis after 2 weeks' (open-label induction) treatment with 0.1% tacrolimus were randomized in a double-blind fashion to treatment with 0.1% tacrolimus once a week, twice a week, or vehicle twice a week, for 10 weeks (maintenance). Significant improvement in erythema, scaling and pruritus compared with baseline was maintained during the maintenance phase in both tacrolimus groups, but not in the vehicle group. The mean recurrence rate according to global assessment was significantly higher in the tacrolimus once-weekly group than in the twice-weekly group. In conclusion, twice-weekly treatment with 0.1% tacrolimus ointment had superior effects in keeping facial seborrhoeic dermatitis in remission.

show abstract

Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults

Cited by 30 publications

References 9 publications

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial

Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial

Proactive Treatment of Adult Facial Seborrhoeic Dermatitis with 0.1% Tacrolimus Ointment: Randomized, Double-blind, Vehicle-controlled, Multi-centre Trial

Contact Info

Product

Resources

About